<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11859864</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.678</article-id><article-id pub-id-type="other">EPP0564</article-id><article-id pub-id-type="pii">S0924933824006783</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Long-term safety and frequency of repeat zuranolone treatment in patients with major depressive disorder rolling over from the randomised CORAL Study into the open-label SHORELINE Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mattingly</surname><given-names>G. W.</given-names></name><xref rid="aff1596" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mathew</surname><given-names>S. J.</given-names></name><xref rid="aff1597" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Parikh</surname><given-names>S. V.</given-names></name><xref rid="aff1598" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aaronson</surname><given-names>S. T.</given-names></name><xref rid="aff1599" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Baune</surname><given-names>B. T.</given-names></name><xref rid="aff1600" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cor0539" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Czysz</surname><given-names>A.</given-names></name><xref rid="aff1601" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nandy</surname><given-names>I.</given-names></name><xref rid="aff1601" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ona</surname><given-names>V.</given-names></name><xref rid="aff1601" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>C.</given-names></name><xref rid="aff1601" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kyaga</surname><given-names>S.</given-names></name><xref rid="aff1602" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Forrestal</surname><given-names>F.</given-names></name><xref rid="aff1602" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Levin</surname><given-names>S.</given-names></name><xref rid="aff1602" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Doherty</surname><given-names>J.</given-names></name><xref rid="aff1601" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mattingly</surname><given-names>G.</given-names></name><xref rid="aff1603" ref-type="aff">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aff1596"><sup>1</sup><institution>
Washington University</institution>, <city>St. Louis</city></aff><aff id="aff1597"><sup>2</sup><institution>Baylor College of Medicine</institution>, <city>Houston</city></aff><aff id="aff1598"><sup>3</sup><institution>University of Michigan</institution>, <city>Ann Arbor</city></aff><aff id="aff1599"><sup>4</sup>Department of Psychiatry, <institution>Sheppard Pratt Health System and University of Maryland School of Medicine</institution>, <city>Baltimore</city>, <country>United States</country></aff><aff id="aff1600"><sup>5</sup>Department of Psychiatry, <institution>University of M&#x000fc;nster</institution>, <city>M&#x000fc;nster</city>, <country>Germany</country></aff><aff id="aff1601"><sup>6</sup><institution>Sage Therapeutics, Inc</institution>.</aff><aff id="aff1602"><sup>7</sup><institution>Biogen Inc</institution>., <city>Cambridge</city></aff><aff id="aff1603"><sup>8</sup><institution>
Washington University</institution>, <city>St. Louis</city>, <state>MO</state>, <country>United States</country></aff><author-notes><corresp id="cor0539"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="653">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S327</fpage><lpage>S328</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824006783a.pdf"/><abstract><sec id="sec3240"><title>Introduction</title><p>Zuranolone (ZRN) is a positive allosteric modulator of both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors and a neuroactive steroid approved as an oral, once-daily, 14-day treatment course for adults with postpartum depression in the US and under investigation for adults with major depressive disorder (MDD). The randomised, double-blind, placebo-controlled, Phase 3 CORAL Study assessed the efficacy and safety of ZRN 50 mg vs placebo, each co-initiated with an open-label standard-of-care antidepressant (ADT). Patients who completed CORAL could roll over into open-label SHORELINE, which assessed the safety and tolerability of ZRN 50 mg and need for repeat treatment courses in adults with MDD.</p></sec><sec id="sec3241"><title>Objectives</title><p>To assess the safety and tolerability (primary endpoint) and need for repeat ZRN 50 mg treatment courses (secondary endpoint) in adults with MDD who previously enrolled in CORAL.</p></sec><sec id="sec3242"><title>Methods</title><p>CORAL enrolled adults (18&#x02013;64 years) with MDD and 17-item Hamilton Rating Scale for Depression (HAMD-17) total score &#x02265;24. After completing the 6-week CORAL Study, patients who enrolled in SHORELINE could enter a 46-week observation period to assess the safety and need for 14-day repeat ZRN treatment course(s), with a total of &#x02264;4 repeat treatment courses permitted. Patients were screened every 2 weeks with the 9-item Patient Health Questionnaire, and scores &#x02265;10 prompted a HAMD-17 assessment within 1 week. Patients with HAMD-17 total score &#x02265;20 were eligible for repeat ZRN course(s) &#x02265;8 weeks after completing the prior ZRN treatment course.</p></sec><sec id="sec3243"><title>Results</title><p>Among the 190 patients from CORAL who rolled over into SHORELINE and received &#x02265;1 ZRN treatment course in either study, 133 (70.0%) had received ZRN+ADT and 57 (30.0%) received placebo+ADT in CORAL. Overall, 118 rollover patients received &#x02265;1 open-label ZRN treatment course in SHORELINE. For patients who received &#x02265;1 ZRN treatment course in either study, 76.8% received 1 (54.2%; 103/190) or 2 (22.6%; 43/190) total ZRN treatment courses across both studies in up to 1 year in study. The most common (&#x0003e;5%) treatment-emergent adverse events (TEAEs) during treatment and 14 days following the last ZRN dose were somnolence (16.1% of patients), dizziness (8.5%), headache (8.5%), fatigue (7.6%), sedation (5.9%), and nausea (5.1%); study-period TEAEs (73.7%; 87/118) for the majority of patients were mild/moderate (69.5%; 82/118) in severity and occurred primarily during the treatment period (58.5%; 69/118). No signals for increased suicidal ideation/behaviour were observed.</p></sec><sec id="sec3244"><title>Conclusions</title><p>Safety and tolerability among rollover patients were consistent with previous studies; most of the TEAEs reported by adults with MDD who received ZRN were mild/moderate in severity. Most patients who rolled over from CORAL to SHORELINE received &#x02264;2 total treatment courses in up to 1 year in study.</p></sec><sec id="sec3245"><title>Disclosure of Interest</title><p>G. Mattingly Grant / Research support from: Akili, Alkermes, Allergan (now AbbVie), Axsome, Boehringer, Janssen, Lundbeck, Medgenics, NLS-1 Pharma AG, Otsuka, Reckitt Benckiser, Roche, Sage, Sunovion, Supernus, Takeda, and Teva, Consultant of: Akili, Alkermes, Allergan (now AbbVie), Axsome, Ironshore, Intra-Cellular Therapies, Janssen, Lundbeck, Neos Therapeutics, Otsuka, Purdue, Rhodes, Sage, Sunovion, Takeda, and Teva, Speakers bureau of: Alkermes, Allergan (now AbbVie), Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, and Takeda, S. Mathew Grant / Research support from: Biohaven Pharmaceuticals, Boehringer-Ingelheim, Janssen, Merck, Sage Therapeutics, Inc., and VistaGen Therapeutics, Consultant of: Allergan (now AbbVie), Alkermes, Almatica Pharma, Axsome Therapeutics, BioXcel Therapeutics, Boehringer-Ingelheim, Clexio Biosciences, COMPASS Pathways, Eleusis, EMA Wellness, Engrail Therapeutics, Greenwich Biosciences, Intra-Cellular Therapies, Janssen, Levo Therapeutics, Perception Neurosciences, Praxis Precision Medicines, Neumora, Neurocrine, Relmada Therapeutics, Sage Therapeutics, Inc., Seelos Therapeutics, Signant Health, and Sunovion, S. Parikh Grant / Research support from: Aifred, Assurex, Janssen, Mensante, Sage Therapeutics, Inc., and Takeda, S. Aaronson Grant / Research support from: COMPASS Pathways and Neuronetics; has served as a consultant to Genomind, Inc., Janssen, LivaNova PLC, Neuronetics; and Sage Therapeutics, Inc., Speakers bureau of: Janssen and Sunovion Pharmaceuticals, Inc., B. Baune Speakers bureau of: Angelini, AstraZeneca, Biogen, Bristol Myers Squibb, Janssen, LivaNova, Lundbeck, Novartis, Otsuka, Pfizer, Servier, Sumitomo Pharma, Wyeth, and Boehringer-Ingelheim, A. Czysz Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., I. Nandy Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., V. Ona Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., C. Brown Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., S. Kyaga Employee of: Biogen Inc., F. Forrestal Employee of: Biogen Inc., S. Levin Employee of: Biogen Inc., J. Doherty Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., G. Mattingly: None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>